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ABSTRACT
Psoriatic arthritis (PsA) is a multifaceted disease,
with a high impact on patients’ psychological
and physical well-being. There is increasing
recognition that assessment of both clinical
aspects of disease and patient identified con-
cerns, such as fatigue, work disability, and
treatment satisfaction need to be addressed.
Only then can we fully understand disease
burden and make well-informed treatment
decisions aimed at improving patients’ lives. In
recent years, there has been much progress in
the development of unidimensional and com-
posite measures of disease activity, as well as
questionnaires capturing the patient’s perspec-
tive in psoriatic disease. Despite these advances,
there remains disagreement amongst clinicians
as to which instruments should be used. As a
consequence, they are yet to receive widespread
implementation in routine clinical practice.
This review aims to summarize currently avail-
able clinical and patient-derived assessment
tools, which will provide clinicians with a
practical and informative resource.
Keywords: Composite measures; Disease acti-
vity; Impact of disease; Outcome measures;
Patient perspective; Psoriatic arthritis; Treat-
ment satisfaction; Work disability
INTRODUCTION
Psoriatic arthritis (PsA) is a heterogeneous dis-
ease with variable involvement of a number of
disease ‘‘domains’’. These include peripheral
arthritis, psoriasis (skin and nail), enthesitis,
dactylitis, and axial disease. In addition to
considering the physician-assessed domains of
disease activity, the overall impact of the disease
on individual patients may encompass addi-
tional issues such as pain, loss of function, and
impairment of quality of life. When designing
clinical studies in PsA, all of these different
aspects of the disease may be important. To
formalize this concept, the Group for Research
and Assessment of Psoriasis and Psoriatic
Arthritis/Outcome Measures in Rheumatology
(GRAPPA-OMERACT) has developed a core
domain set for PsA which highlights the
domains relevant to this disease. The ‘‘inner
circle’’ of the core set is recommended to be
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measured in all clinical trials and includes
musculoskeletal and skin disease activity, pain,
patient global assessment, physical function,
health related quality of life (HRQoL), fatigue,
and systemic inflammation. Additional
domains considered important were economic
cost, emotional well-being, participation, and
structural damage [1].
The TIght Control Of Psoriatic Arthritis
(TICOPA) trial confirmed the benefit of regular
disease activity assessment using objective out-
come measures [2]. As a result of this, new rec-
ommendations for the management of PsA
focus on the importance of regular assessment
of disease activity, as well as disease impact
from the patient’s perspective to guide thera-
peutic decisions [3–5]. Thus, the use of objective
outcome measures is now becoming more rou-
tine in clinical practice outside of the research
setting.
In this review, we summarize data for mea-
sures of individual disease domains, as well as
newer composite measures of disease activity in
general, with a focus on measures that may be
practical and informative in routine clinical use.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
INDIVIDUAL DOMAIN MEASURES
Arthritis
All measures of peripheral arthritis are based on
tender and swollen joint counts but are often
combined with some patient-reported out-
comes to give a composite measure. Given the
heterogeneity of joint involvement in PsA, a
more complete 68/66 joint counts is required
rather than reduced joint counts in rheumatoid
arthritis (RA), which can miss significant
amounts of active disease [6]. Many studies in
PsA have used the disease activity score (DAS)
borrowed from RA to assess arthritis, but the
reduced joint count within the DAS28 in par-
ticular is a concern and the cut points used in
RA have not been validated in PsA.
In clinical trials, the primary outcome of new
drug randomized controlled trials (RCTs) has
always been the American College of Rheuma-
tology 20% (ACR20) response. The ACR
response criteria are borrowed from RA but are
usually modified to use a 68/66 joint count.
They are reported as a binary outcome for those
who achieve a 20, 50, or 70% improvement in
tender and swollen joint counts, plus three of
the following: physician global, patient global,
patient pain, function, and C reactive protein
(CRP)/erythrocyte sedimentation rate (ESR).
While these perform well at differentiating drug
and placebo in polyarticular patients [7], they
may not perform as well in oligoarticular
patients and are not particularly feasible in the
clinic.
More recently the disease activity in PsA
(DAPSA) has been developed from the disease
activity in reactive arthritis (DAREA) scale [8].
This includes a 68/66 joint count summed with
a patient global, patient pain score, and CRP
level. The DAPSA provides a continuous score of
arthritis activity and has validated cut points for
remission (\4) and low disease activity (\ 14)
[9]. DAPSA disease activity states have been
shown to correlate with functional status and
structural progression on radiographs providing
further evidence of their validity [10]. However,
research to date has focused on polyarticular
patients where disease activity is proportional
to joint counts but may be less representative in
oligoarthritis patients where the DAPSA high
disease activity level is unlikely to ever be
reached despite high impact of disease.
Enthesitis
There are two key clinical measures of enthesitis
in PsA that have been shown to be valid. During
development, the sites for the Leeds Enthesitis
Index (LEI) were chosen by reducing the Man-
der entheseal sites to those most commonly
tender in PsA patients. It includes just three
sites bilaterally (lateral epicondyles, medial
condyles of the femur, and Achilles tendons)
[11]. The second measure, the Spondyloarthritis
Consortium of Canada (SPARCC) enthesitis
score is composed of sites that were found to be
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commonly involved in the imaging of spondy-
loarthritis (PsA and ankylosing spondylitis (AS))
patients. It contains 16 sites (eight bilaterally)
with some overlap with the LEI [12]. Both scores
have been used in a number of PsA clinical trials
and as of yet there is no clear superiority of
either measure. However, it should be noted
that clinical assessment of pain at entheseal
insertions has been shown to have a poor cor-
relation with ultrasound evidence of enthesitis
[13]. For this reason, current studies investigat-
ing treatment of enthesitis as a primary or key
secondary outcome have also included imaging
outcome measures to provide additional face
validity.
Dactylitis
Dactylitis is a typical feature of PsA where
inflammation occurs in multiple tissues within
a single digit. In the majority of clinical studies,
dactylitis has been assessed by a simple count of
dactylitic digits, sometimes multiplied by the
0–3 tenderness grading used in the Ritchie
index. While these simple counts can show
sensitivity in clinical trials, a more detailed
quantified scoring system called the Leeds
Dactylitis Instrument (LDI) has also been
developed [14]. The dactylometer measures the
circumference of swollen digits at the base of
the finger. This provides a quantifiable defini-
tion of dactylitis—an increase in circumference
of[ 10% more than the contralateral digit. The
LDI as a measure then combines this level of
swelling using the circumference measurement
with a score (either 0-3 or 0/1) for tenderness
[14]. The LDI score has been shown to be
responsive in clinical trials and has a larger
effect size than simple dactylitis counts [14, 15].
Axial Disease
Axial disease in PsA is probably the least well
defined aspect of the disease. There are also
significant issues with the outcome measures
used in axial PsA. The outcomes tested have all
been adopted from AS. The Bath AS Disease
Activity Index (BASDAI) has been used to mea-
sure disease activity in axial PsA and has been
shown to correlate with other disease activity
measures. However, it is not able to differentiate
between axial and peripheral musculoskeletal
disease activity with high scores in those with
active peripheral PsA only. This lack of speci-
ficity limits its use, as it will not be able to dif-
ferentiate individual domains of disease
activity.
In recent years, the AS Disease Activity Score
(ASDAS) in axial SpA has been developed. This
composite score includes a number of questions
from the BASDAI combined with the CRP result.
This score has been validated in axial SpA
including in patients with axial PsA [16, 17] but
due to its components, it is likely to be affected
by the same problem as the BASDAI, with the
scores being affected by peripheral disease
activity.
Skin
The most commonly used outcome measure in
psoriasis clinical trials is the Psoriasis Area and
Severity Index (PASI), which is a composite of
body surface area (BSA), erythema, induration,
and scaling of psoriasis on different areas of the
body (head, trunk, upper limbs, lower limbs)
[18]. Although it is often used in some health-
care settings, it is relatively burdensome in
clinical practice. Additionally, in PsA patients
who have mild skin disease, it may be repre-
sentative of disease burden and less responsive
to change.
Simpler measures have focused on only
measuring body surface area or have used sim-
pler assessments of overall disease activity, such
as the static Physician Global Assessment
(sPGA). This can be recorded on a scale of 1
(clear) to 6 (very severe) but assesses plaque
quality without assessing body surface area.
More recently, work has been undertaken
looking at a combination of the two—sPGA 9
BSA to allow a simple feasible measure that
encompasses both body surface area and a
characterization of the psoriasis plaque [19].
Validation work has shown that this simpler
measure shows good concordance with PASI
and could be used as a PASI proxy in routine
clinical practice [20].
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COMPOSITE MEASURES
OF DISEASE ACTIVITY
Given that PsA is so heterogeneous with
involvement of multiple domains in each
patient, a number of composite measures of
psoriatic disease have been developed to mea-
sure the overall disease burden.
The first of these is a measure of disease state
developed specifically to be a target of therapy.
The minimal disease activity (MDA) criteria
encompass seven different items that are asses-
sed individually. The criteria state that patients
are in MDA if they achieve five of the seven
criteria: tender joint count B 1, swollen joint
count B 1, enthesitis count B 1, PASI B 1 or
BSA B 3, patient global visual analogue score
(VAS) B 20 mm, patient pain VAS B 15 mm
and health assessment questionnaire (HAQ)
B 0.5 [21]. The advantage of these criteria is
that they assess multiple domains of disease in
order to establish disease control; however,
assess these individually rather than combining
them into one single score. The MDA criteria
have been shown to be associated with lower
radiographic progression [22] and patient
impact of disease [23], as well as improved
quality of life, functional ability, and work sta-
bility [24]. They have been recommended as a
target of therapy in PsA by the international
treat-to-target (T2T) taskforce [5] and the
GRAPPA-OMERACT group [25].
The principle limitation of the MDA criteria
is that they only define a disease state and do
not allow assessment of different levels of dis-
ease activity. The first true disease activity
composite measure in PsA was the Composite
Psoriatic Disease Activity Index (CPDAI) [26],
which was based on the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) treatment grid system [27]. Each
domain of PsA (peripheral joints, skin, entheses,
dactylitis, and axial disease) is assessed using a
measure of disease activity and a measure of
disease impact, and these are summed together
to create a total score of 0-15. The CPDAI cor-
relates well with patient and physician global
assessments [26] and was able to differentiate
between different etanercept doses in the
Psoriasis Randomized Etanercept STudy in Sub-
jects with Psoriatic Arthritis (PRESTA) trial [28],
showing that it identifies other aspects of dis-
ease beyond the peripheral arthritis.
Two further measures were developed by the
international GRAPPA group through a specific
project called GRACE (GRAPPA Composite
Exercise). This study used two different
methodologies to analyze data on 503 patients
assessed at baseline, 3, 6, and 12 months. The
‘‘gold standard’’ for disease activity was the
decision of the physician to change or escalate
treatment. The PsA Disease Activity Score
(PASDAS) is a weighted index developed using
similar methodology to the RA disease activity
score. This includes seven components identi-
fied on principle component analysis (arthritis,
enthesitis, dactylitis, CRP, and patient-reported
outcomes). The GRACE index contains eight
domain measures transformed using desirability
functions and then combined [29]. Both of
these new measures performed well in the
development dataset [29] and in retrospective
analyses of RCTs [30], including correlation
with function and radiographic progression
[31]. The effect sizes of these indices were
greater than CPDAI, DAPSA, and DAS28,
meaning that smaller sample sizes may be
required for future trials using these measures.
Candidate cut-offs for different levels of disease
activity and response criteria have also been
developed for the PASDAS, GRACE, and CPDAI
[32].
THE PATIENT PERSPECTIVE—
PATIENT-REPORTED OUTCOME
MEASURES (PROMS)
In order to capture the full impact of psoriatic
disease on an individual’s physical and psy-
chological well-being, there has been a para-
digm shift in recent years towards the use of
outcome measures which encompass real-life
outcomes important to patients alongside the
validated metrics already mentioned [25].
Patient-Reported Outcome Measures (PROMs)
are derived directly from patients and have been
found to be reliable indicators of disease status
and predictors of long-term outcomes [33–35].
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This review will now focus on tools available to
assess the impact of psoriatic disease on
patients, their ability to work, and satisfaction
with treatment.
Measuring the Impact of Psoriatic Disease
from a Patient’s Perspective
The Psoriatic Arthritis Impact of Disease (PsAID)
questionnaire was recently developed by the
European League Against Rheumatism (EULAR)
taskforce and aims to reflect the impact of PsA
from the patient perspective [36]. This patient-
derived outcome measure is specific to PsA and
is quick and simple to perform. It encompasses
12 domains, which address physical and psy-
chological aspects of psoriatic disease, such as
work, fatigue, and physical function. Each
domain is assessed by a single question with
patient response on a numeric rating scale 0–10,
with higher results indicating a more severe
condition. Each domain carries a different
weight, with pain having the greatest effect
[36]. Two versions of the PsAID questionnaire
have been developed: the 12-item questionnaire
(PSAID12) for clinical practice and a nine-item
questionnaire (PSAID9) for use in clinical trials.
The cut-off value for a patient-acceptable symp-
tom state is B 4 for both scores [36].
The PSAID questionnaire was validated in an
international cross-sectional and longitudinal
study of more than 470 patients, across 13
countries and was shown to have high reliabil-
ity, generalizability, and strong correlation with
patient global assessment (PGA) [36]. Holland
et al. conducted a prospective cohort study of
129 patients with PsA to further investigate the
validity of the PsAID questionnaire and deter-
mine the relationship between individual PsAID
questions and established PROMs [37]. They
concluded that both PSAID9 and PSAID12
questionnaires are reliable measures of impact
of disease in PsA and are feasible in clinical
practice. The PsAID questionnaire, and the
individual items within it, strongly correlate
with other PROMs [37]. While this lends sup-
port to the notion that conventional PROMs are
in fact sensitive to patient concerns, the strong
correlation of PsAID across a range of
established PROMs could eliminate the need for
multiple questionnaires, thereby reducing
questionnaire burden for patients and improv-
ing feasibility in both clinical and research set-
tings. Similar results were demonstrated in an
Italian PsA cohort, with an emphasis on the
importance of clinical judgement, in those
patients with co-existent fibromyalgia, as this
can influence the final PSAID score [38].
While the PsAID questionnaire is not a
measure of disease activity, it does have the
potential as an outcome measure to enable
individualized treatment through the identifi-
cation and targeting of those aspects of disease
deemed most important to each patient.
Although the PsAID questionnaire has been
found to be sensitive to change [36, 37], inde-
pendent cohorts and interventional clinical
trials, including patients treated with biologic
disease-modifying anti-rheumatic drugs
(bDMARDs), are needed to further validate the
PsAID questionnaire.
Work Disability in Psoriatic Arthritis
It is now recognized that work disability (WD) is
an important functional outcome for PsA
patients [36]. WD encompasses a spectrum of
disabilities, ranging from absenteeism (time
missed from work due to health reasons), pre-
senteeism (reduced effectiveness at work due to
health reasons), productivity loss (absenteeism
plus presenteeism) through to unemployment.
Levels of unemployment and WD are high in
PsA, with unemployment levels ranging from
20 to 50% [39–45] and WD as high as 39% [39],
and translates into significant individual and
societal economic costs [39, 41, 45, 46].
A large multicenter study of 400 PsA patients
assessed WD using the Work Productivity and
Activity Impairment (WPAI) questionnaire and
found that of the 236 participants who were in
work, absenteeism, presenteeism, and produc-
tivity loss rates were 14, 39, and 46%, respec-
tively. A further 26% of participants were
unemployed. Greater age, recent onset of dis-
ease, and worse physical function were associ-
ated with higher risk of unemployment, while
patient-reported employer helpfulness exerted a
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strongly positive influence on patients remain-
ing in employment [47].
Furthermore, studies have shown that better
disease control through the use of anti-TNFs
ameliorates work disability in patients with PsA
[41, 48, 49], with the LOPAS II study demon-
strating a 30% improvement in presenteeism
(p\ 0.001) and 40% improvement in work
productivity (p\ 0.001) [48]. These findings
suggest that work disability in active PsA is
reversible with modern therapy, which could
have major implications for both the individual
as well as the wider society.
While it is recognized that WD is an impor-
tant patient-outcome measure and several
questionnaires measuring WD are available
[50], no consensus exists on which tool to use.
This is in part due to the poor correlation
between these tools’ ability to estimate com-
ponents of WD [51] and lack of validation in
PsA. The Work Productivity and Activity
Impairment (WPAI) questionnaire is one such
measure of work productivity. This question-
naire consists of six questions, asking patients
to report the degree to which their condition, in
this case PsA, has affected their ability to work
and perform regular activities over the preced-
ing week. Four outcome measures are generated
(absenteeism, presenteeism, productivity loss,
and general activity impairment). While the
WPAI questionnaire is yet to be validated in
PsA, its use is supported by the OMERACT
(Outcomes Measures in Rheumatology) group
[52] and it is the most patient-favored work-re-
lated measure, with 29% of patients reporting it
as being the most relevant to them [52].
Treatment Satisfaction in Psoriatic
Arthritis
The expansion of treatment options available to
patients with PsA has led to significant
improvements in patient outcomes. However,
with this comes different modalities, frequen-
cies of drug administration, and side-effects,
which can considerably influence patient qual-
ity of life. One study found that 45.5% of
patients with PsA are dissatisfied with their
treatment [53]. Suboptimal medication adher-
ence is known to impact the success of treat-
ment outcomes, patient quality of life and has
economic implications [54–56]. Patient satis-
faction with treatment can predict adherence to
medication regimens in chronic diseases, with
convenience of use and side-effects being
prominent predictors of adherence [57]. In
addition, patient satisfaction with medications
is positively correlated with health-related
quality of life [57]. Assessment and under-
standing of patient preference, attitudes
towards treatment, and medication satisfaction
are necessary in ensuring uptake and adherence
to these medications and improving patient
outcomes.
The Treatment Satisfaction Questionnaire
for Medication (TSQM) is a widely used, reliable,
and validated instrument to assess patients’
satisfaction with their treatment [58]. This
questionnaire has been used in other rheumatic
diseases and psoriasis [59–62]; however, to our
knowledge has not been evaluated in PsA. The
TSQM version 1.4 consists of 14 items, which
explore four domains: side-effects, effectiveness,
convenience, and global satisfaction with the
medication. Each domain is scored 0–100, with
higher scores indicating better treatment satis-
faction. Abbreviated versions of TSQM have
since been developed: TSQM Version II (11
items) [63] and TSQM-9 (9 items) [64]. Assess-
ment of treatment satisfaction through the use
of the TSQM provides an opportunity to
understand and incorporate patients’ perspec-
tives into shared clinical decision-making and
better identify those patients at risk of poor
adherence. This enables clinicians to target
their interventions towards the aspects respon-
sible for poor concordance. PsA studies using
validated measures in real-life clinical condi-
tions are needed to assess patient satisfaction
with conventional synthetic DMARDs and bio-
logical DMARDS. This will be critical in
improving patient satisfaction and ultimately
ensuring better adherence, patient outcomes,
and health-related quality of life in psoriatic
arthritis.
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CONCLUSIONS
It is well recognized that psoriatic disease is a
complex condition, encompassing a multitude
of clinical manifestations, which significantly
impact patients’ function and quality of life. In
recent years, there has been a paradigm shift
towards the development of disease activity
indices that are responsive to clinical measures
and also patient-reported outcomes, thereby
capturing the full burden of disease. Widespread
implementation of these instruments in routine
clinical practice and research trials will be piv-
otal to providing clinicians with a better
understanding of the full patient experience, in
aiding treatment decisions and providing fur-
ther details on patient satisfaction and efficacy
of novel therapies in PsA.
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